D. E. Shaw & Co., Inc. Vertex Pharmaceuticals Inc Put Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $473,452 - $507,444	1,400 New	1,400 $486,000
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $2.74 Million - $3.06 Million	-10,000 Reduced 55.56%	8,000 $2.32 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $563,904 - $702,120	-2,400 Reduced 11.76%	18,000 $5.07 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $6.75 Million - $7.96 Million	-30,500 Reduced 59.92%	20,400 $5.32 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $8.55 Million - $10.8 Million	-48,300 Reduced 48.69%	50,900 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $7.29 Million - $8.16 Million	40,200 Added 68.14%	99,200 $18 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $6.56 Million - $7.74 Million	35,000 Added 145.83%	59,000 $11.9 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $207,020 - $241,310	-1,000 Reduced 4.0%	24,000 $5.16 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $758,000 - $885,650	5,000 Added 25.0%	25,000 $4.08 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $2.96 Million - $3.24 Million	20,000	20,000 $3.04 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.